The VERSANT HIV-1 RNA 3.0 Assay (bDNA) demonstrates excellent precision across the entire reporting range (variability range calculated from data in product inserts). The high level of precision afforded by bDNA allows three-fold changes in viral load to be distinguished. Variability associated with the PCR assay could make it less useful for monitoring patients on antiretroviral therapy.¹

Correlation with PCR

Minimizing the total cost of ownership in viral load testing through decreased hands-on time, reduced consumables and improved space utilization

The next generation bDNA analyzer, the VERSANT 440 Molecular System, was compared to the current System 340 for overall operational cost of operation. The VERSANT 440 was able to significantly reduce costs and improve overall workflow.

• VERSANT 440 vigilance time (hands-on manipulations plus incubation time except initial target hybridization) was approximately 37% lower than the System 340 for HIV-1 and 64% for HCV bDNA
• Disposables were approximately 12% and 31% lower for HIV-1 and HCV bDNA, respectively, with VERSANT 440
• Biohazardous solid waste was approximately two-fold lower on the VERSANT 440

Reference:
Expert Rev Mol Diagn. 2007 Nov;7(6):713-22
'Cost assessment of the automated VERSANT 440 Molecular System versus the semi-automated System 340 bDNA Analyzer platforms.', Elbeik T, Loftus RA, Beringer S
Professional Habitat Design, LLC; Health Management Institute, Inc., c/o 584 Castro Street 349, San Francisco, CA 94114, USA. t.elbeik@phdllc.net
Article

Siemens VERSANT HIV-1 RNA 3.0 Assay (bDNA) is easier to use than other molecular assays.

• Minimal hands-on time – Requires only one laboratory technologist
• Familiar ELISA-like format – Easy to learn and master

• One-room technology – Eliminates need for separate, dedicated clean room necessary for PCR methods

References
1. Amplicor HIV-1 Monitor Test v. 1.5, Standard and UltraSensitive procedures, U.S. IVD product insert; and VERSANT HIV-1 RNA 3.0 Assay (bDNA) U.S. IVD product insert.
2. Sherlock, C et al. 2003. Performance of the Bayer VERSANT® HIV-1 RNA 3.0 Assay Compared with the Roche Cobas Amplicor HIV-1 Monitor™ v1.5 Assay with a Focus on Low Copy-Number Samples. 19th Clinical Virology Symposium poster.

VERSANT® HIV-1 RNA 3.0 Assay (bDNA) is for in vitro diagnostic use only by clinical professionals for the direct quantitation of HIV-1 RNA in plasma of HIV-1 infected individuals.

CE Marked and FDA Approved
TaqMan and Amplicor are registered trademarks of Roche